Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 19 entries
Sorted by: Best Match Show Resources per page
[Silent myocardial ischemia. Contribution of coronarography].

Annales de cardiologie et d'angeiologie

Gilgenkrantz JM.
PMID: 3619379
Ann Cardiol Angeiol (Paris). 1987 May;36(5):239-43.

Coronary angiography enables to determine the true frequency of silent myocardial ischemia (SMI) and specify its prognostic value. Three types of populations are studied. First, patients who are completely asymptomatic and without any past history. The prevalence of coronary...

Cite
Gilgenkrantz JM. Ischémie myocardique silencieuse. Apport de la coronarographie. [Silent myocardial ischemia. Contribution of coronarography]. Ann Cardiol Angeiol (Paris). 1987;36(5):239-43
Gilgenkrantz, J. M. (1987). Ischémie myocardique silencieuse. Apport de la coronarographie. [Silent myocardial ischemia. Contribution of coronarography]. Annales de cardiologie et d'angeiologie, 36(5), 239-43.
Gilgenkrantz, J M. "Ischémie myocardique silencieuse. Apport de la coronarographie." [Silent myocardial ischemia. Contribution of coronarography]. Annales de cardiologie et d'angeiologie vol. 36,5 (1987): 239-43.
Gilgenkrantz JM. Ischémie myocardique silencieuse. Apport de la coronarographie. [Silent myocardial ischemia. Contribution of coronarography]. Ann Cardiol Angeiol (Paris). 1987 May;36(5):239-43. French. PMID: 3619379.
Copy Download .nbib Format: NLM
[Organization of scientific medical periodicals].

Bulletin de la Societe des sciences medicales du Grand-Duche de Luxembourg

Lequime J, Legrain M, Chevalier V, Gerday R, Gilgenkrantz JM, Herlant M, Huguier M.
PMID: 544089
Bull Soc Sci Med Grand Duche Luxemb. 1979;116(1):21-30.

No abstract available.

Cite
Lequime J, Legrain M, Chevalier V, et al. Organisation des périodiques médicaux scientifiques. [Organization of scientific medical periodicals]. Bull Soc Sci Med Grand Duche Luxemb. 1979;116(1):21-30
Lequime, J., Legrain, M., Chevalier, V., Gerday, R., Gilgenkrantz, J. M., Herlant, M., & Huguier, M. (1979). Organisation des périodiques médicaux scientifiques. [Organization of scientific medical periodicals]. Bulletin de la Societe des sciences medicales du Grand-Duche de Luxembourg, 116(1), 21-30.
Lequime, J, et al. "Organisation des périodiques médicaux scientifiques." [Organization of scientific medical periodicals]. Bulletin de la Societe des sciences medicales du Grand-Duche de Luxembourg vol. 116,1 (1979): 21-30.
Lequime J, Legrain M, Chevalier V, Gerday R, Gilgenkrantz JM, Herlant M, Huguier M. Organisation des périodiques médicaux scientifiques. [Organization of scientific medical periodicals]. Bull Soc Sci Med Grand Duche Luxemb. 1979;116(1):21-30. French. PMID: 544089.
Copy Download .nbib Format: NLM
[Autism, the untraceable gene: from science to business].

Medecine sciences : M/S

Gilgenkrantz S.
PMID: 22480660
Med Sci (Paris). 2012 Mar;28(3):329-30. doi: 10.1051/medsci/2012283024. Epub 2012 Apr 06.

No abstract available.

Cite
Gilgenkrantz S. Autisme, le gène introuvable - De la science au business Bertrand Jordan. [Autism, the untraceable gene: from science to business]. Med Sci (Paris). 2012;28(3):329-30doi: 10.1051/medsci/2012283024.
Gilgenkrantz, S. (2012). Autisme, le gène introuvable - De la science au business Bertrand Jordan. [Autism, the untraceable gene: from science to business]. Medecine sciences : M/S, 28(3), 329-30. https://doi.org/10.1051/medsci/2012283024
Gilgenkrantz, Simone. "Autisme, le gène introuvable - De la science au business Bertrand Jordan." [Autism, the untraceable gene: from science to business]. Medecine sciences : M/S vol. 28,3 (2012): 329-30. doi: https://doi.org/10.1051/medsci/2012283024
Gilgenkrantz S. Autisme, le gène introuvable - De la science au business Bertrand Jordan. [Autism, the untraceable gene: from science to business]. Med Sci (Paris). 2012 Mar;28(3):329-30. doi: 10.1051/medsci/2012283024. Epub 2012 Apr 06. French. PMID: 22480660.
Copy Download .nbib Format: NLM
Targeting cell-intrinsic metabolism for antifibrotic therapy.

Journal of hepatology

Gilgenkrantz H, Mallat A, Moreau R, Lotersztajn S.
PMID: 33631228
J Hepatol. 2021 Jun;74(6):1442-1454. doi: 10.1016/j.jhep.2021.02.012. Epub 2021 Feb 22.

In recent years, there have been major advances in our understanding of the mechanisms underlying fibrosis progression and regression, and how coordinated interactions between parenchymal and non-parenchymal cells impact on the fibrogenic process. Recent studies have highlighted that metabolic...

Cite
Gilgenkrantz H, Mallat A, Moreau R, et al. Targeting cell-intrinsic metabolism for antifibrotic therapy. J Hepatol. 2021;74(6):1442-1454doi: 10.1016/j.jhep.2021.02.012.
Gilgenkrantz, H., Mallat, A., Moreau, R., & Lotersztajn, S. (2021). Targeting cell-intrinsic metabolism for antifibrotic therapy. Journal of hepatology, 74(6), 1442-1454. https://doi.org/10.1016/j.jhep.2021.02.012
Gilgenkrantz, Helene, et al. "Targeting cell-intrinsic metabolism for antifibrotic therapy." Journal of hepatology vol. 74,6 (2021): 1442-1454. doi: https://doi.org/10.1016/j.jhep.2021.02.012
Gilgenkrantz H, Mallat A, Moreau R, Lotersztajn S. Targeting cell-intrinsic metabolism for antifibrotic therapy. J Hepatol. 2021 Jun;74(6):1442-1454. doi: 10.1016/j.jhep.2021.02.012. Epub 2021 Feb 22. PMID: 33631228.
Copy Download .nbib Format: NLM
[Primary pulmonary arterial hypertension: five new case reports].

Revue medicale de Nancy

PERNOT C, GILGENKRANTZ J, HURIET C, TENETTE C.
PMID: 13421187
Rev Med Nancy. 1957 Feb;82:123-42.

No abstract available.

Cite
PERNOT C, GILGENKRANTZ J, HURIET C, et al. L'hypertension artérielle pulmonaire primitive: cinq nouvelles observations. [Primary pulmonary arterial hypertension: five new case reports]. Rev Med Nancy. 1957;82:123-42
PERNOT, C., GILGENKRANTZ, J., HURIET, C., & TENETTE, C. (1957). L'hypertension artérielle pulmonaire primitive: cinq nouvelles observations. [Primary pulmonary arterial hypertension: five new case reports]. Revue medicale de Nancy, 82123-42.
PERNOT, C, et al. "L'hypertension artérielle pulmonaire primitive: cinq nouvelles observations." [Primary pulmonary arterial hypertension: five new case reports]. Revue medicale de Nancy vol. 82 (1957): 123-42.
PERNOT C, GILGENKRANTZ J, HURIET C, TENETTE C. L'hypertension artérielle pulmonaire primitive: cinq nouvelles observations. [Primary pulmonary arterial hypertension: five new case reports]. Rev Med Nancy. 1957 Feb;82:123-42. French. PMID: 13421187.
Copy Download .nbib Format: NLM
[A stone ablation in Oberhaslach in Alsace, in 1810].

La Revue du praticien

Gilgenkrantz S, Gourevitch D.
PMID: 32237636
Rev Prat. 2019 Nov;69(9):1040-1041.

No abstract available.

Cite
Gilgenkrantz S, Gourevitch D. Une opération de la pierre à Oberhaslach en Alsace, en 1810. [A stone ablation in Oberhaslach in Alsace, in 1810]. Rev Prat. 2019;69(9):1040-1041
Gilgenkrantz, S., & Gourevitch, D. (2019). Une opération de la pierre à Oberhaslach en Alsace, en 1810. [A stone ablation in Oberhaslach in Alsace, in 1810]. La Revue du praticien, 69(9), 1040-1041.
Gilgenkrantz, Simone, and Gourevitch, Danielle. "Une opération de la pierre à Oberhaslach en Alsace, en 1810." [A stone ablation in Oberhaslach in Alsace, in 1810]. La Revue du praticien vol. 69,9 (2019): 1040-1041.
Gilgenkrantz S, Gourevitch D. Une opération de la pierre à Oberhaslach en Alsace, en 1810. [A stone ablation in Oberhaslach in Alsace, in 1810]. Rev Prat. 2019 Nov;69(9):1040-1041. French. PMID: 32237636.
Copy Download .nbib Format: NLM
EGFR: A Master Piece in G1/S Phase Transition of Liver Regeneration.

International journal of hepatology

Collin de L'hortet A, Gilgenkrantz H, Guidotti JE.
PMID: 23050157
Int J Hepatol. 2012;2012:476910. doi: 10.1155/2012/476910. Epub 2012 Sep 23.

Unraveling the molecular clues of liver proliferation has become conceivable thanks to the model of two-third hepatectomy. The synchronicity and the well-scheduled aspect of this process allow scientists to slowly decipher this mystery. During this phenomenon, quiescent hepatocytes of...

Cite
Collin de L'hortet A, Gilgenkrantz H, Guidotti JE. EGFR: A Master Piece in G1/S Phase Transition of Liver Regeneration. Int J Hepatol. 2012;2012:476910doi: 10.1155/2012/476910.
Collin de L'hortet, A., Gilgenkrantz, H., & Guidotti, J. E. (2012). EGFR: A Master Piece in G1/S Phase Transition of Liver Regeneration. International journal of hepatology, 2012476910. https://doi.org/10.1155/2012/476910
Collin de L'hortet, Alexandra, et al. "EGFR: A Master Piece in G1/S Phase Transition of Liver Regeneration." International journal of hepatology vol. 2012 (2012): 476910. doi: https://doi.org/10.1155/2012/476910
Collin de L'hortet A, Gilgenkrantz H, Guidotti JE. EGFR: A Master Piece in G1/S Phase Transition of Liver Regeneration. Int J Hepatol. 2012;2012:476910. doi: 10.1155/2012/476910. Epub 2012 Sep 23. PMID: 23050157; PMCID: PMC3461622.
Copy Download .nbib Format: NLM
[ERDITI, The European Rare Diseases Therapeutic Initiative: a public-private partnership is promoting research on new treatments for rare diseases].

Medecine sciences : M/S

Gilgenkrantz S, Borensztein P.
PMID: 16386228
Med Sci (Paris). 2006 Jan;22(1):84-6. doi: 10.1051/medsci/200622184.

No abstract available.

Cite
Gilgenkrantz S, Borensztein P. Développer des traitements pour les maladies rares: ERDITI, un partenariat public-privé pour la recherche thérapeutique. [ERDITI, The European Rare Diseases Therapeutic Initiative: a public-private partnership is promoting research on new treatments for rare diseases]. Med Sci (Paris). 2006;22(1):84-6doi: 10.1051/medsci/200622184.
Gilgenkrantz, S., & Borensztein, P. (2006). Développer des traitements pour les maladies rares: ERDITI, un partenariat public-privé pour la recherche thérapeutique. [ERDITI, The European Rare Diseases Therapeutic Initiative: a public-private partnership is promoting research on new treatments for rare diseases]. Medecine sciences : M/S, 22(1), 84-6. https://doi.org/10.1051/medsci/200622184
Gilgenkrantz, Simone, and Borensztein, Pascale. "Développer des traitements pour les maladies rares: ERDITI, un partenariat public-privé pour la recherche thérapeutique." [ERDITI, The European Rare Diseases Therapeutic Initiative: a public-private partnership is promoting research on new treatments for rare diseases]. Medecine sciences : M/S vol. 22,1 (2006): 84-6. doi: https://doi.org/10.1051/medsci/200622184
Gilgenkrantz S, Borensztein P. Développer des traitements pour les maladies rares: ERDITI, un partenariat public-privé pour la recherche thérapeutique. [ERDITI, The European Rare Diseases Therapeutic Initiative: a public-private partnership is promoting research on new treatments for rare diseases]. Med Sci (Paris). 2006 Jan;22(1):84-6. doi: 10.1051/medsci/200622184. French. PMID: 16386228.
Copy Download .nbib Format: NLM
[Autism, the untraceable gene: from science to business].

Medecine sciences : M/S

Gilgenkrantz S.
PMID: 22480660
Med Sci (Paris). 2012 Mar;28(3):329-30. doi: 10.1051/medsci/2012283024. Epub 2012 Apr 06.

No abstract available.

Cite
Gilgenkrantz S. Autisme, le gène introuvable - De la science au business Bertrand Jordan. [Autism, the untraceable gene: from science to business]. Med Sci (Paris). 2012;28(3):329-30doi: 10.1051/medsci/2012283024.
Gilgenkrantz, S. (2012). Autisme, le gène introuvable - De la science au business Bertrand Jordan. [Autism, the untraceable gene: from science to business]. Medecine sciences : M/S, 28(3), 329-30. https://doi.org/10.1051/medsci/2012283024
Gilgenkrantz, Simone. "Autisme, le gène introuvable - De la science au business Bertrand Jordan." [Autism, the untraceable gene: from science to business]. Medecine sciences : M/S vol. 28,3 (2012): 329-30. doi: https://doi.org/10.1051/medsci/2012283024
Gilgenkrantz S. Autisme, le gène introuvable - De la science au business Bertrand Jordan. [Autism, the untraceable gene: from science to business]. Med Sci (Paris). 2012 Mar;28(3):329-30. doi: 10.1051/medsci/2012283024. Epub 2012 Apr 06. French. PMID: 22480660.
Copy Download .nbib Format: NLM
[Three female physicians of the Montpellier faculty at the turn of the 19th century].

Histoire des sciences medicales

Fontaine J, Gilgenkrantz S.
PMID: 27029136
Hist Sci Med. 2015 Jul-Dec;49(3):441-50.

As a part of a study on the census of female students listed in medicine at the faculty of Montpellier since it opened to women in 1868 until the end of the Third Republic, we selected three women who...

Cite
Fontaine J, Gilgenkrantz S. Portraits de trois femmes médecins de la'faculté de Montpellier au tournant du XIXème siècle. [Three female physicians of the Montpellier faculty at the turn of the 19th century]. Hist Sci Med. 2015;49(3):441-50
Fontaine, J., & Gilgenkrantz, S. (2015). Portraits de trois femmes médecins de la'faculté de Montpellier au tournant du XIXème siècle. [Three female physicians of the Montpellier faculty at the turn of the 19th century]. Histoire des sciences medicales, 49(3), 441-50.
Fontaine, Jacqueline, and Gilgenkrantz, Simone. "Portraits de trois femmes médecins de la'faculté de Montpellier au tournant du XIXème siècle." [Three female physicians of the Montpellier faculty at the turn of the 19th century]. Histoire des sciences medicales vol. 49,3 (2015): 441-50.
Fontaine J, Gilgenkrantz S. Portraits de trois femmes médecins de la'faculté de Montpellier au tournant du XIXème siècle. [Three female physicians of the Montpellier faculty at the turn of the 19th century]. Hist Sci Med. 2015 Jul-Dec;49(3):441-50. French. PMID: 27029136.
Copy Download .nbib Format: NLM
[No title available]

Medecine sciences : M/S

Gilgenkrantz H.
PMID: 34895456
Med Sci (Paris). 2021 Dec;37:23-28. doi: 10.1051/medsci/2021222. Epub 2021 Dec 13.

No abstract available.

Cite
Gilgenkrantz H. Axel Kahn à l’ère de la thérapie génique Les années 1980-2000. . Med Sci (Paris). 2021;37:23-28doi: 10.1051/medsci/2021222.
Gilgenkrantz, H. (2021). Axel Kahn à l’ère de la thérapie génique Les années 1980-2000. . Medecine sciences : M/S, 3723-28. https://doi.org/10.1051/medsci/2021222
Gilgenkrantz, Hélène. "Axel Kahn à l’ère de la thérapie génique Les années 1980-2000." . Medecine sciences : M/S vol. 37 (2021): 23-28. doi: https://doi.org/10.1051/medsci/2021222
Gilgenkrantz H. Axel Kahn à l’ère de la thérapie génique Les années 1980-2000. . Med Sci (Paris). 2021 Dec;37:23-28. doi: 10.1051/medsci/2021222. Epub 2021 Dec 13. French. PMID: 34895456.
Copy Download .nbib Format: NLM
[What about good in all this? A human passion].

Medecine sciences : M/S

Gilgenkrantz H.
PMID: 34851286
Med Sci (Paris). 2021 Nov;37(11):1060-1061. doi: 10.1051/medsci/2021123. Epub 2021 Dec 01.

No abstract available.

Cite
Gilgenkrantz H. Et le Bien dans tout ça ? (Axel Kahn) - Une passion humaine. [What about good in all this? A human passion]. Med Sci (Paris). 2021;37(11):1060-1061doi: 10.1051/medsci/2021123.
Gilgenkrantz, H. (2021). Et le Bien dans tout ça ? (Axel Kahn) - Une passion humaine. [What about good in all this? A human passion]. Medecine sciences : M/S, 37(11), 1060-1061. https://doi.org/10.1051/medsci/2021123
Gilgenkrantz, Hélène. "Et le Bien dans tout ça ? (Axel Kahn) - Une passion humaine." [What about good in all this? A human passion]. Medecine sciences : M/S vol. 37,11 (2021): 1060-1061. doi: https://doi.org/10.1051/medsci/2021123
Gilgenkrantz H. Et le Bien dans tout ça ? (Axel Kahn) - Une passion humaine. [What about good in all this? A human passion]. Med Sci (Paris). 2021 Nov;37(11):1060-1061. doi: 10.1051/medsci/2021123. Epub 2021 Dec 01. French. PMID: 34851286.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 19 entries